Repligen Corporation research snapshot
RGEN AI stock analysis currently reads Repligen as a specialized bioprocessing supplier with improving customer demand, a strategic cell therapy acquisition, and a demanding valuation. At the August 3, 2026 data cutoff, the latest public close was $141.01 on July 31, 2026 and the verified market capitalization was about $7.96 billion. Repligen reported $204 million of second-quarter 2026 revenue, up 12% as reported and 13% on an organic basis, and raised full-year 2026 guidance to $813 million to $835 million of revenue with adjusted diluted EPS of $2.03 to $2.09. The company also announced a definitive agreement to acquire BioLife Solutions for about $1.5 billion, funded with 64% Repligen stock and 36% cash, which is expected to close in the fourth quarter of 2026. The upside case depends on continued organic growth, margin recovery, BioLife integration, and execution of its transformation plan. The main constraint is price: this RGEN AI stock analysis sees strong business quality but only medium investment certainty at roughly 193x trailing earnings, 62x forward earnings, and 71x trailing free cash flow. This page is for informational use and is not investment advice.
Current price
$141.01
Market cap
$7.96 billion
AI score
64 / 100
Rating
High-quality bioprocessing franchise with accelerating demand, a $1.5 billion acquisition, and valuation risk
Trend status
Above the 50-day and 200-day moving averages with neutral momentum and limited distance to the longer average
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Repligen sells filtration, chromatography, process analytics, proteins, and fluid-management technologies used to develop and manufacture biologic drugs. Customers pay when its tools improve yield, control, reliability, or production scale, and Q2 2026 revenue grew 13% on an organic basis. | High |
| Moat | The moat comes from validated products, process know-how, installed workflows, switching friction, brand trust, and a portfolio built across upstream and downstream bioprocessing. The BioLife deal adds an embedded biopreservation media franchise with recurring revenue, but large customers can negotiate and alternative suppliers remain active. | Medium |
| Management | Management accelerated organic growth, raised full-year 2026 guidance, and agreed to acquire BioLife Solutions for about $1.5 billion in a mix of 64% stock and 36% cash expected to close in Q4 2026. The next test is whether the acquisition adds per-share EPS while integration and transformation risks stay contained. | Medium |
| Financial trend | FY2025 revenue rose 16.36% to $738.26 million and GAAP net income recovered to $48.89 million from a $25.51 million loss in 2024. TTM revenue was $785.10 million and TTM free cash flow was $111.97 million, and Q2 2026 adjusted operating income rose 55% year over year. | High |
| Valuation | At $141.01, the exact valuation check gives about 193.22x TTM EPS, 62.11x forward EPS, 10.14x sales, 3.77x book value, and 71.08x free cash flow. The market is paying for a recovery in growth and profitability, so conventional margin of safety is limited. | High for the calculation |
| Technical trend | The July 31 snapshot put RGEN at $141.01, above its 50-day average of $133.68 and 200-day average of $139.76, with RSI at 52.10. The trend is constructive, but the stock sits only about 1% above the longer average, so the setup has less room for error than before. | Medium |
| Risk level | Risk is medium-high. Bioprocessing order cycles, customer inventory, large-account concentration, BioLife integration and stock-based consideration, manufacturing execution, acquisitions, tariffs, foreign exchange, and valuation compression can all affect results. | High |
| AI confidence | AI confidence is high for disclosed facts and calculations, but medium for the forward thesis because no model can reliably know the timing of customer orders, industry recovery, deal close, or future multiples. | High for data, medium for outlook |
| Investment certainty | Investment certainty is medium-low: the business has credible technology and cash generation, while the current price requires sustained growth, better operating leverage, and successful acquisition integration to justify the valuation. | Medium-low |
RGEN AI stock forecast
The RGEN AI stock forecast is scenario-based rather than a promised price target. The required three-scenario calculation used the FY2026 adjusted EPS guidance midpoint of about $2.06, three years, 20%, 12%, and 3% annual EPS growth, and 45x, 32x, and 22x exit PE assumptions. It produced calculated reference values of about $160, $93, and $50. The wider ranges below reflect uncertainty around bioprocessing demand, BioLife integration, margins, acquisitions, and market multiples.
$155 to $185
More likely if 2026 guidance is met or exceeded, organic growth stays near or above the raised 10.5% to 13.5% range, BioLife closes in Q4 2026 and delivers the expected EPS accretion, transformation lifts operating margins, and investors continue to value RGEN as a durable compounder.
$90 to $115
More likely if revenue grows in line with the raised $813 million to $835 million guidance, 2026 adjusted EPS guidance of $2.03 to $2.09 is broadly achieved, the BioLife integration stays on schedule, and the valuation multiple normalizes toward a lower growth-company range. The calculated base reference was about $93.
$45 to $70
More likely if biopharma customers delay capacity spending, inventory correction returns, BioLife integration or the stock-heavy consideration disappoints, margins remain below plan, or the market assigns a much lower multiple to slower cash-flow growth. The calculated bear reference was about $50.
RGEN AI technical analysis
RGEN AI technical analysis uses the latest public StockAnalysis snapshot available at the August 3, 2026 cutoff. RGEN closed at $141.01 on July 31, 2026, above the reported 50-day moving average of $133.68 and 200-day moving average of $139.76. RSI was 52.10, beta was 1.06, and average 20-day volume was about 1.21 million shares. These are static reference levels, not live signals, so confirm them in a current chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $141.01 | Public close on July 31, 2026. Refresh the quote before using any technical framework. |
| Near support | $139.76 | Reported 200-day moving average at the cutoff. A sustained loss would weaken the longer trend. |
| Deeper support | $133.68 | Reported 50-day moving average at the cutoff. A decisive break would invalidate a medium-term trend-following setup. |
| Reference resistance | $150 to $160 | A round-number reference zone above the latest close, not a verified horizontal chart level. The consensus analyst target of about $185.70 is well above this zone. Use volume and price action to confirm any breakout. |
| 50-day moving average | $133.68 | Price was above this average in the July snapshot, supporting intermediate momentum. |
| 200-day moving average | $139.76 | The close at $141.01 was only about 1% above this average, so the longer trend has little room for error. |
| Momentum | RSI 52.10 | Neutral momentum in this snapshot, neither overbought nor oversold. RSI can stay elevated during a trend and should not be used alone. |
| Volume | 20-day average about 1.21 million shares | Above-average volume would make a breakout or breakdown more informative, especially around earnings, guidance, and BioLife deal milestones. |
| Volatility | 5-year beta 1.06 | Historical beta was close to the market average, but bioprocessing order news and acquisition headlines can create event volatility beyond beta. |
| Invalidation | Decisive close below the live 200-day average, then $133.68 | A break below $139.76 would weaken the longer trend; a confirmed break below the live 50-day average would invalidate this trend framework. |
RGEN AI trading strategy
The RGEN AI trading strategy is a rules-based research framework, not personalized advice. It combines price confirmation with bioprocessing order trends, customer inventory, product mix, margin guidance, cash flow, BioLife deal and integration milestones, and the next earnings date.
Wait for RGEN to hold above the live 200-day average and for any move through the $150 to $160 reference zone to be confirmed by above-average volume and unchanged earnings assumptions. Review the upcoming earnings date, the BioLife close timing, and guidance before relying on a chart pattern.
Define risk before entry. A confirmed close below the live 200-day average near $139.76 can invalidate the longer trend framework, while a break below the 50-day average near $133.68 signals deeper weakness.
If RGEN pulls back toward $139.76 or $133.68 without a negative order, guidance, or deal update, wait for stabilization and compare volume with customer demand, gross margin, cash flow, and the valuation multiple before treating the move as mean reversion.
Do not average down solely because the stock fell. The setup fails if support breaks alongside weaker bioprocessing demand, delayed customer projects, BioLife integration issues, margin pressure, or a reduced outlook.
Track organic revenue, adjusted operating margin, chromatography and process analytics growth, order trends, customer inventory, cash and marketable securities, free cash flow, BioLife close timing and integration, the Polymem divestiture, and the effect of the stock component of the acquisition.
Refresh the forecast after earnings, guidance changes, BioLife deal milestones, a major acquisition, a customer concentration disclosure, a material tariff or foreign exchange move, or a large price gap. Avoid stale technical levels around results.
Investment research summary
Repligen supplies the tools and consumables that help biopharmaceutical companies develop, scale, and control production processes. Its customers pay for higher yield, shorter timelines, reproducibility, and lower process risk rather than for a single end drug. The BioLife acquisition adds biopreservation media and cell processing tools for the cell therapy workflow.
The moat is built from validated products, process knowledge, regulatory and quality records, installed workflows, customer training, and a broad portfolio across filtration, chromatography, proteins, analytics, and fluid management. Switching costs are strongest when a product is embedded in a validated manufacturing process, and BioLife adds a deeply embedded consumables platform with recurring revenue.
The thesis fails if customers reduce capacity spending, inventory remains elevated, alternatives take share, large accounts pressure price, the BioLife deal dilutes per-share value or integration slips, acquisitions dilute returns, manufacturing quality slips, or new modality growth does not convert into recurring demand. A high multiple can amplify each disappointment.
Management accelerated organic growth, raised 2026 guidance, and is using about $1.5 billion, mostly in stock, to acquire BioLife Solutions. The capital allocation question is whether the deal and the ongoing transformation produce better per-share cash returns than preserving financial flexibility, and whether integration risk stays contained.
Biologics, mRNA, cell and gene therapy, and continuous manufacturing increase the need for higher-productivity and better-controlled processes. BioLife positions Repligen in the cell therapy market, but the timing of the opportunity depends on biotech funding, clinical success, customer plant utilization, and how much process value suppliers can capture.
At $141.01, RGEN trades around 193x TTM earnings, 62x forward earnings, and 71x TTM free cash flow. The price assumes continued growth, margin recovery, and successful BioLife integration beyond the raised 2026 guidance. Margin of safety requires durable organic growth, operating leverage, and disciplined capital allocation, not just a large bioprocessing market.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Price, market capitalization, and shares | $141.01 July 31, 2026 close, $7.96 billion market cap, and 56.44 million shares. Price multiplied by shares matched reported market cap. | StockAnalysis RGEN statistics | August 3, 2026 |
| Q2 2026 results and raised guidance | $204 million Q2 2026 revenue, up 12% as reported and 13% organic. Q2 adjusted diluted EPS was $0.54. Full-year 2026 guidance was raised to $813 million to $835 million of total reported revenue and $2.03 to $2.09 of adjusted diluted EPS, with organic growth of 10.5% to 13.5%. | Repligen Q2 2026 results | August 3, 2026 |
| BioLife Solutions acquisition | Definitive agreement announced July 22, 2026 to acquire BioLife Solutions for about $1.5 billion enterprise value, comprised of 64% Repligen common stock and 36% cash, or $31.00 per BioLife share. The deal is expected to close in Q4 2026 and to be accretive to adjusted EPS by at least $0.05 in year one and $0.25 in year two. | Repligen acquisition press release | August 3, 2026 |
| FY2025 revenue and five-year trend | $738.26 million FY2025 revenue, up 16.36% year over year; 2024 revenue was $634.44 million, 2023 revenue was $632.36 million, and 2022 revenue was $801.54 million. | StockAnalysis RGEN financials | August 3, 2026 |
| FY2025 profit and TTM free cash flow | $48.89 million net income in FY2025 versus a $25.51 million loss in 2024. TTM free cash flow was $111.97 million and FY2025 free cash flow was $93.90 million. | StockAnalysis RGEN financials and statistics | August 3, 2026 |
| Cash, debt, and net cash | $810.45 million cash and equivalents, $690.94 million debt, and $119.51 million net cash in the latest StockAnalysis snapshot. The company reported $810 million of cash, cash equivalents, and marketable securities at June 30, 2026. | StockAnalysis and Repligen Q2 2026 results | August 3, 2026 |
| Valuation ratios | 193.22 trailing PE, 62.11 forward PE, 10.14 price to sales, 3.77 price to book, 71.08 price to free cash flow, and 1.41% free cash flow yield. | StockAnalysis RGEN statistics | August 3, 2026 |
| Analyst consensus | Strong Buy consensus from 22 analysts with an average price target of $185.70, about 31.5% above the July 31 close. The three-year revenue growth forecast was 15.47% and the three-year EPS growth forecast was 26.00%. | StockAnalysis RGEN forecast data | August 3, 2026 |
| Technical indicators | $141.01 price, $133.68 50-day average, $139.76 200-day average, RSI 52.10, beta 1.06, and about 1.21 million 20-day average volume. | StockAnalysis RGEN statistics | August 3, 2026 |
| Addressable market and product scope | Repligen estimates a roughly $20 billion global bioprocessing product market and about $13 billion of addressable market. Its product scope includes filtration, fluid management, chromatography, process analytics, and proteins, and the BioLife deal adds biopreservation media for cell and gene therapy. | Repligen annual report and company materials | August 3, 2026 |
This RGEN AI stock analysis is an information tool, not investment advice, a solicitation, or a promise of returns. Forecast ranges are scenario estimates based on available data and assumptions, and they may be wrong. The BioLife Solutions acquisition is pending and may not close as planned. Verify current prices, filings, technical levels, taxes, liquidity, and your own risk tolerance before making financial decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
